RT @tom_watson: Another uplifting tweet.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @paulwaugh: More good news for everyone to wake up to. https://t.co/VmNpWJTb4F
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/nLTdF0aOyD
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @VishnuNDTV: Huge development for India.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Encouraging news. Good to see detailed analysis in a peer-reviewed publication. This study augurs well for the next step - the ability of this vaccine to protect against COVD-19.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Another uplifting tweet.
@Particle2Wave Read the paper for yourself https://t.co/wAD9yhY7iR
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @DrDerekConnolly: The results of the Oxford Jenner Institute COVID Vaccine are stunning ⭐️ ChAdOx1 nCoV-19 appears to be better tolerat…
"Immunisation with ChAdOx1 nCoV-19 results in development of neutralising antibodies against SARS-CoV-2 in almost 100% of participants including older adults without severe comorbidities, with higher levels in boosted compared with non-boosted groups."
RT @VishnuNDTV: Huge development for India. https://t.co/MMxWnQD7Lz
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults - nice work Maheshi! https://t.co/eqO0KXbm4p
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
$AZN Oxford https://t.co/d6aZnNheuY
Some more good news...
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Nice to see this data in a peer-reviewed journal 👇 #oxfordvaccine #COVID19 #LetTheDataDoTheTalking https://t.co/IEQvUObxPF
RT @DrDerekConnolly: The results of the Oxford Jenner Institute COVID Vaccine are stunning ⭐️ ChAdOx1 nCoV-19 appears to be better tolerat…
Good news for India
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Huge development for India.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
My sister took part in this trial. I hope she got the proper vaccine not the placebo 🙌
encouraging phase 2 onews regrading Oxford vaccine ... good immune response in the elderly 🙏
RT @paulwaugh: More good news for everyone to wake up to.
RT @Prof_Marciniak: The Oxford vaccine showing very promising results across aga groups “Neutralising titres were achieved by 14 days afte…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @MikeyKayNYC: If you can’t read it all. Read the last two paragraphs #Covid_19 #Vaccine https://t.co/OtdtyQ1Uw3
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
88% de participantes (15-55 años) de fase 2 de estudio de la vacuna Oxford-AstraZeneca, tuvieron efectos adversos. Reconocen que 2.3% del total tuvieron "eventos adversos graves", dicen que no fue por la vacuna, pero no dicen cómo están seguros de ello...
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Researchers at Oxford say there are "encouraging" signs their coronavirus vaccine is showing a strong immune response in adults in their 60s and 70s https://t.co/chacdc0MMk
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @paulwaugh: More good news for everyone to wake up to.
Safety and immunogenicity of #ChAdOx1 nCoV-19 #vaccine administered in a prime-boost regimen in young and old adults (#COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/hndoS6bO9H. #SARSCoV2 #COVID19 #coronavirus #vaccines $AZN
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @paulwaugh: More good news for everyone to wake up to.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
@1nationtory Not sure what’s different at first glance but it comes from this Lancet paper published today. If you were being cynical you’d say that this has been put out to keep it in the news whilst we wait for the delayed phase 3 results... https://t
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Christmas present 👇👇👇
RT @Prof_Marciniak: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/ThvkPQ5E3K
RT @paulwaugh: More good news for everyone to wake up to.
RT @Prof_Marciniak: The Oxford vaccine showing very promising results across aga groups “Neutralising titres were achieved by 14 days afte…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
"ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across all age groups after a boost dose." 나이든 사람에게서 더 tolerated 하다네요. 랜싯의 논문 (자료보관용). https://t.co/FUQyiUYHX8
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
The results of the Oxford Jenner Institute COVID Vaccine are stunning ⭐️ ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across all age groups after a boost dose https://t.co/p0fj3FWvuy
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @Prof_Marciniak: The Oxford vaccine showing very promising results across aga groups “Neutralising titres were achieved by 14 days afte…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
The Oxford vaccine showing very promising results across aga groups “Neutralising titres were achieved by 14 days after the boost vaccination in 208 (>99%) of 209 recipients of a boost vaccination” https://t.co/ufikDqUBJK
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @paulwaugh: More good news for everyone to wake up to. https://t.co/VmNpWJTb4F
RT @mariaramirezNY: Los resultados de la fase 2 del ensayo de la vacuna de Oxford explicados (ya está en la fase 3, que es la final y sobre…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/vqMGzuvqaw
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
More good news for everyone to wake up to.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @CNBCJou: Good news: The Lancet reporting encouraging results out of the Oxford vaccine phase 2 trials. Phase 3 results not out yet (whe…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/qibqN5oE8r
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Good news: The Lancet reporting encouraging results out of the Oxford vaccine phase 2 trials. Phase 3 results not out yet (where you get an efficacy number)
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @MrMBrown: Full study is here - https://t.co/F8lH8PAu5j (h/t @Adamlinton1)
Hope!
@gorka_orive ¿Que opinión te merecen estos resultados? Gracias.